By reducing tumoral PDGF-B, the metformin treatment resulted in the suppression of angiogenesis and a more mature vasculature of metastatic breast cancers, thus limiting the distant metastasis and improving chemosensitization. Here, PDGFB is linked to breast carcinoma.